Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232868 · ClinicalTrials.gov registry record · NA
Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT01232868 is a NA study that has completed, run by Emory University. The registered enrollment target is 66 participants.
The verdict
NCT01232868, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular. This could be explained by a defect in the early responses of an ageing immune system. A better understanding of the basic immunological mechanisms that mediate vaccine efficacy is incomplete. Such information is critical and could greatly decrease both the cost and the time to new vaccine development particularly for the geriatric population. In this trial, the investigators will study the immunologic differences of an FDA approved licensed influenza vaccine between a younger and an older group. Twenty two healthy volunteers between the age of 25-40 and forty four healthy volunteers above the age of 65 will be enrolled in the study. Each participant in the study will be given one flu shot. Blood work will be obtained prior to vaccination, one day, three days, seven days, fourteen days, as well as one month and six months after vaccination. Throughout the duration of the study, the participants will be monitored for safety.
Interventions
- BIOLOGICAL trivalent Influenza vaccine (TIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01232868
The ClinicalTrials.gov registry entry for NCT01232868 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which trivalent Influenza vaccine (TIV) is the first listed.
NCT01232868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01232868 about?
NCT01232868 is a clinical study titled "Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly". Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular. This could be explained by a defect in the early responses of an ageing immune system....
What is the current status of trial NCT01232868?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2010-10. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01232868?
The interventions under investigation include: trivalent Influenza vaccine (TIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01232868?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.